Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab

NCT04928573 · clinicaltrials.gov ↗

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Sponsor

Libbs Farmacêutica LTDA